Our team is committed to finding the cause and creating new therapies for all forms of cardiovascular disease. The Bioficial Organs Program is Directed by Dr. Stuart K Williams. Dr. Williams’ curriculum Vitae can be downloaded here: Williams CV 1-1-2015
A brief biography of Dr Williams:
Dr. Stuart Williams received his Ph.D. in Cell Biology from the University of Delaware followed by postdoctoral training in Pathology at the Yale School of Medicine. During the period 1980 to 1990 he held a faculty appointment at Jefferson Medical College where he was Director of Research in the Department of Surgery. In 1990 Dr. Williams joined the faculty at the University of Arizona and founded the University of Arizona Biomedical Engineering Program creating a research and educational link between the Medical School and College of Engineering. He held faculty positions jointly in Biomedical Engineering, Surgery, Physiology and Materials Science and Engineering. In 2007 Dr. Williams was selected as the Scientific Director of the newly established Cardiovascular Innovation Institute, a partnership between Jewish Hospital and the University of Louisville in Louisville Kentucky. He recently established the Bioficial Organs Program to create human tissues and organs for clinical therapeutics and in vitro drug efficacy and toxicity testing using a patient’s own cells. Central to this effort is the use of 3D bioprinting technologies. Dr. Williams’ research interests have focused on medical devices and regenerative medicine. He developed and patented the first methods to use fat-derived stem and regenerative cells for therapeutic use. He has maintained continuous funding from the National Institutes of Health since 1979. Dr. Williams has authored over 300 scientific publications. His entrepreneurial spirit has resulted in 18 issued US patents with numerous patents pending. He has founded six biotechnology companies; maintained active managerial positions and has been an active consultant to the medical device, regenerative medicine and pharmaceutical community. He is a Fellow of the American Heart Association and a Fellow of the American Institute of Medical and Biological Engineering.